Setmelanotide vs Lixisenatide
Head-to-head comparison of Setmelanotide (Setmelanotide Acetate) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Setmelanotide | Lixisenatide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Setmelanotide Acetate | Exendin-4-derived GLP-1 receptor agonist |
| Molecular Weight | N/A | 4858 Da |
| Half-Life | Approximately 11-16 hours | 2-4 hours |
| Amino Acids | N/A | 44 |
| Typical Dose | 1-3 mg daily | 10-20 mcg daily |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 80 | 400 |
| Research Status | Clinical | Approved |
Setmelanotide Benefits
- ✓reduced hyperphagia
- ✓body-weight reduction
- ✓MC4R pathway activation
- ✓improved satiety signaling
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
Setmelanotide Dosing
1 mg SC daily|titrate weekly to 2-3 mg/day|follow study or label-based escalation
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
Setmelanotide Side Effects
- ⚠hyperpigmentation
- ⚠nausea
- ⚠injection-site reactions
- ⚠fatigue
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Research Overview
Setmelanotide
Setmelanotide has shown clinically meaningful reductions in hunger and weight in POMC, PCSK1, and LEPR-related obesity. It is one of the most important mechanistic peptides for rare-disease obesity research.
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.